Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 1.00 |
| ▸ | ESR1 | P03372 | 11/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373697 | 0.91 | ESR2 (0.83) | ESR2ESR1ABHD6CA1CA2 | |
| SCHEMBL23395334 | 0.88 | ESR2 (0.79) | ESR2ESR1ABHD6CA1CA2 | |
| SCHEMBL25604135 | 0.87 | ESR2 (0.77) | ESR2ESR1ABHD6HDAC8HDAC6 | |
| SCHEMBL25206226 | 0.87 | ESR2 (0.76) | ESR2ESR1ABHD6HDAC8HDAC6 | |
| SCHEMBL3874010 | 0.84 | ESR2 (0.72) | ESR2ESR1ABHD6HDAC8HDAC6 | |
| SCHEMBL419896 | 0.84 | ESR2 (0.72) | ESR2ESR1ABHD6HDAC8HDAC6 | |
| SCHEMBL14100712 | 0.84 | ESR2 (0.72) | ESR2ESR1ABHD6HDAC8HDAC6 | |
| SCHEMBL4179872 | 0.84 | ESR2 (0.72) | ESR2ESR1ABHD6CA1CA2 | |
| SCHEMBL29963966 | 0.84 | ESR2 (0.72) | ESR2ESR1ABHD6HDAC8HDAC6 | |
| SCHEMBL10067649 | 0.81 | ESR2 (0.68) | ESR2ESR1ABHD6HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-6096752-A | Method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives | HEINONEN PETRI (FI) | 2000-08-01 | — | — | US | disclosed |
| US-5912342-A | SYNTHESIS OF COMBINATORIAL LIBRARIES BY COMPUTER CONTROLLED ROBOT | HEINONEN PETRI (FI) | 1999-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | ESR2 1084/4885ESR1 791/4885ABHD6 3657/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | ESR2 1084/4885ESR1 791/4885ABHD6 3657/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | ESR2 1084/4885ESR1 791/4885ABHD6 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.